Ko S M
Department of Psychological Medicine, National University of Singapore.
Br J Clin Pract. 1995 Jan-Feb;49(1):36-9.
Previously thought of as merely an interesting syndrome, obsessive-compulsive disorder is now estimated to afflict 1%-2% of the world's population. Over the past decade extensive research into the epidemiology, aetiology, pathophysiology and pharmacological treatment of this condition has greatly improved its prognosis. This is largely due to the development of the serotonergic group of antidepressants, the selective serotonin reuptake inhibitors (SSRIs), which have consistently demonstrated antiobsessional properties. Monoamine oxidase inhibitors (MAOIs) and lithium have also contributed to the amelioration of symptoms in some patients. Other pharmacological treatment, often prescribed in combination with the SSRIs, include the antipsychotic drugs, benzodiazepines, and anticonvulsants.
强迫症曾被认为只是一种有趣的综合征，现在估计全球有1%-2%的人口受其困扰。在过去十年中，对这种疾病的流行病学、病因学、病理生理学和药物治疗进行了广泛研究，大大改善了其预后。这主要归功于血清素能类抗抑郁药，即选择性5-羟色胺再摄取抑制剂（SSRI）的开发，这些药物一直显示出抗强迫特性。单胺氧化酶抑制剂（MAOI）和锂也有助于改善一些患者的症状。其他药物治疗通常与SSRI联合使用，包括抗精神病药物、苯二氮卓类药物和抗惊厥药物。
